Jeff Kelly, PhD

Jeffery W. Kelly is Professor of Chemistry at The Scripps Research Institute. He is a leading expert in protein misfolding disorders and discovered the first approved drug (tafamidis vyndaqel; Pfizer) for transthyretin amyloidosis. He was a Co-founder of FoldRx (acquired by Pfizer) and Proteostasis.

He has served as a board member at Yumanity, Proteostasis, Scripps, George Hewitt Foundation, and Amyloidosis Research Consortium.